• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

A shot in the dark: Safety, efficacy, research lacking for pediatric medications

Pediatric dermatologist Elaine Siegfried, M.D., says that, about 80 percent of the time, she has to treat patients with drugs that have no FDA-approved indication or have never been formally studied in children.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
Multicenter Study Sheds Light on Pediatric MMP
April 3rd 2025

Multicenter Study Sheds Light on Pediatric MMP

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD
March 12th 2025

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD
February 26th 2025

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD

Reviewing Complex Cases: Topicals for Pediatric AD
February 25th 2025

Reviewing Complex Cases: Topicals for Pediatric AD

© 2025 MJH Life Sciences

All rights reserved.